Bryan Dalphy

Engagement with the Government regarding the Life Science Fund seeking partnership and funding to support completion of Phase I and Phase II clinical research program associated to AMR (antimicrobial resistance) Antimicrobial Resistance (AMR) - Seek funding and support for pilot projects making anti-infective medications available to equity seeking populations, helping to combat AMR. Also discuss any applicable conditions regarding this funding. Programs and policy to support Canadian biomanufacturing and access to medicines and vaccines for Canadians. National Immunization Strategy and policies and programs that impact public access to vaccines and disease prevention in Canada. Patented Medicines Review Board (PMPRB), certified under the Patent Act and whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Engagement with federal officials regarding the Biomanufacturing & Life Sciences Strategy and policies and programming related to biomanufacturing in Canada Access to medicines - government policies, processes, legislation, and/or regulation with potential impact on access to medicines in Canada. Trade-related matters, including policies and tariffs impacting medicines and vaccines. Policies and programs related to the health of new immigrants to Canada. Policies, programs, and funding related to Canada's Sexually Transmitted and Blood-Borne Infections (STBBI) Action Plan 2024-2030. Engagement with federal officials regarding Health Emergency Readiness Canada. The National Pharmaceutical Strategy (NPS) as agreed by First Ministers in 2004. Advocacy for ways to increase access to medicines and vaccines for Canadian patients. The Common Drug Review (CDR) process for reviewing new drugs and providing listing recommendations to publicly funded drug benefit plans in Canada. Ensuring the access needs of Canadian patients are met by advocating on activities undertaken in the context of the CDR. Science and Technology (S&T) Strategy: Mobilizing Science and Technology to Canada's Advantage. Advocacy for measures which will allow for commercialization in health care to occur and for Canada to remain competitive internationally on Intellectual Property and other fronts. Public Services and Procurement Canada (PSPC) Integrity Framework - Clarifying the process for procurement of vaccines and possibly pharmaceuticals under the evolving procurement framework. Patented Medicines (Notice of Compliance) Regulations which seek to balance the protection of Intellectual Property (IP) and patents with cost containment. Advocacy to ensure that IP rights are respected and internationally competitive in order to promote Research and Development. Legislation, regulations, policies and programs concerning the federal government's response to COVID-19, including pandemic preparedness, pharmaceutical and vaccine supply-chain management, and general administration of justice. Food and Drugs Act and the bill formerly known as Bill C-51: An Act to amend the Food and Drugs Act and to make consequential amendments to other Acts. Specifically, with respect to the renewal of the drug approval process. Advocacy to ensure that Canada's review and approval process is timely, safe, effective, competitive and consistent with other jurisdictions. FedDev Ontario Advanced Manufacturing Fund - advancing manufacturing of innovative pharmaceutical products in southern Ontario Engage with government to strengthen the Priority Review for Drug Submissions process. Engage the Government regarding the need for clear and efficient procurement processes for COVID-19 medical countermeasures, including COVID-19 therapeutics, to ensure access for Canadians. Engagement with the Government regarding the Strategic Innovation Fund Drug Re-importation - Raise awareness regarding the potential risks to drug and vaccine supply fo

strategic policy objectives for the MedTech sector regarding 2026 CUSMA review. export permits and export controls • Government investments in Artificial Intelligence (AI) compute infrastructure; • Government policy considerations on health data trust and privacy. Substances addressed in the third phase of the Chemicals Management Plan. Support from ISED, with respect to Strategic Innovation Fund Medical device cost recovery schemes with respect to filing fees Engage in pre-market and post-market regulatory requirements to ensure efficient and predictable processes that supports safety, effectiveness, quality, and Canada’s competitiveness in the medical device sector. Amendments to Copyright Act, regarding Technology Protection Measures (TPMs)

Advocacy related to university engagement in Canadian priorities in artificial intelligence, data systems and related computing science and energy subjects, including but not limited to specific calls for proposals. Advocacy for university initiatives related to Canadian priorities across the defence spectrum, including initiatives relevant to both Defence and Veterans' Affairs, among other federal departments. Advocacy to enhance support for university research mobilization and commercialization activities. Research security, with respect to international research partnerships Discussions with Innovation, Science and Economic Development Canada and other relevant departments and agencies regarding the role of universities in supporting federal innovation initiatives, policies and programs. Discussions regarding research and development initiatives and federal support related to energy and environment, and climate change research, innovation, commercialization, talent and knowledge mobilization. Discussions regarding official language funding amounts and mechanisms. Discussions about the Copyright Act and details of its implementation in a post-secondary setting. Advocacy to secure support in the budget for post-secondary education, research, innovation, and science and technology. Advocacy to secure federal support to develop and upgrade university infrastructure, including but not limited to research and learning facilities, digital infrastructure, and transit infrastructure. Advocacy to increase support for university research, including research funding and granting programs administered by the tri-agencies (SSHRC, NSERC, CIHR) and other departments and agencies. Advocacy to improve immigration policies and programs for prospective and current university students, faculty, and staff. Advocacy to ensure that proposals to develop or amend federal legislation, regulations, policies or programs that directly or indirectly impact the post-secondary system reflect the needs of universities and support our research and education mission. Advocacy to enhance student supports, including but no limited to Canada Student Grants and Loans, the Canada Graduate Scholarship Program, supports for Indigenous students, and work-integrated learning programs. Advocacy to advance Canadian leadership in priority areas to support world class research, talent attraction and retention, and knowledge mobilization. Advocacy related to reconciliation efforts, including but not limited to the Truth and Reconciliation Commission's Calls to Action

Soutien financier dans le développement des connectivités entre les appareils diagnostics et l'application. Support à l'exportation et à la commercialisation Le développement d'un outil d'aide dans la gestion des données dans la lutte à la Résistance antimicrobienne (RAM). Et sa promotion à l'international